Paul Kruszka, MD, is the Chief Medical Officer of GeneDx, a leader in genomic testing and analysis for rare disorders, which was acquired by Sema4 in April 2022. Paul is responsible for leading genomic research in rare diseases and promoting access to genomic medicine.
Paul is a board-certified clinical geneticist who uses genomic and precision medicine to enhance the delivery of healthcare to individuals with rare diseases. Paul’s career is motivated by the idea that genetic technology can be used to have a beneficial impact on people’s lives and that there are still many challenges to implementing genomic medicine.
Prior to working at GeneDx, Paul spent a decade at the National Institutes of Health conducting genomic research and taking care of individuals with rare genetic diseases. He is credited with the clinical and molecular delineation of multiple novel genetic conditions.
After attending medical school at the University of Michigan, Paul completed a family medicine residency at the University of Virginia. He also completed a clinical genetics residency at the National Human Genome Research Institute at the National Institutes of Health.
Interview with Paul (published October 2022) https://mendelspod.com/podcasts/paul-kruszka-genedxsema4-groundbreaking-...
